Article ; Online: Insomnia: Pharmacologic Therapy.
2017 Volume 96, Issue 1, Page(s) 29–35
Abstract: Insomnia accounts for more than 5.5 million visits to family physicians each year. Although behavioral interventions are the mainstay of treatment, pharmacologic therapy may be necessary for some patients. Understanding the risks and benefits of insomnia ...
Abstract | Insomnia accounts for more than 5.5 million visits to family physicians each year. Although behavioral interventions are the mainstay of treatment, pharmacologic therapy may be necessary for some patients. Understanding the risks and benefits of insomnia medications is critical. Controlled-release melatonin and doxepin are recommended as first-line agents in older adults; the so-called z-drugs (zolpidem, eszopiclone, and zaleplon) should be reserved for use if the first-line agents are ineffective. For the general population with difficulty falling asleep, controlled-release melatonin and the z-drugs can be considered. For those who have difficulty staying asleep, low-dose doxepin and the z-drugs should be considered. Benzodiazepines are not recommended because of their high abuse potential and the availability of better alternatives. Although the orexin receptor antagonist suvorexant appears to be relatively effective, it is no more effective than the z-drugs and much more expensive. Sedating antihistamines, antiepileptics, and atypical antipsychotics are not recommended unless they are used primarily to treat another condition. Persons with sleep apnea or chronic lung disease with nocturnal hypoxia should be evaluated by a sleep specialist before sedating medications are prescribed. |
---|---|
MeSH term(s) | Benzodiazepines/administration & dosage ; Benzodiazepines/therapeutic use ; Doxepin/administration & dosage ; Doxepin/therapeutic use ; Humans ; Hypnotics and Sedatives/administration & dosage ; Hypnotics and Sedatives/therapeutic use ; Melatonin/administration & dosage ; Melatonin/agonists ; Melatonin/therapeutic use ; Sleep Initiation and Maintenance Disorders/drug therapy |
Chemical Substances | Hypnotics and Sedatives ; Benzodiazepines (12794-10-4) ; Doxepin (1668-19-5) ; Melatonin (JL5DK93RCL) |
Language | English |
Publishing date | 2017-07-01 |
Publishing country | United States |
Document type | Journal Article ; Review |
ZDB-ID | 412694-4 |
ISSN | 1532-0650 ; 0002-838X ; 0572-3612 |
ISSN (online) | 1532-0650 |
ISSN | 0002-838X ; 0572-3612 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.B 848: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.